While there have been few direct studies of CamK-A in thyroid cancer, NF-κB signaling is known to be constitutively activated in aggressive thyroid cancers, particularly those with BRAFV600E mutations, and NB-κB signaling has been shown to have increased invasive properties and poor prognosis. The gene discussed is CAMK2A; the disease is thyroid gland carcinoma.